Abstract:BackgroundSurgery plays an important role in the management of endometrial cancer at all stages, particularly early clinical stage. There are still many unanswered questions regarding optimal surgical management of endometrial cancer, particularly regarding which patients should undergo lymphadenectomy. The aim of this study was to evaluate the role of preoperative cancer antigen 125 (CA125) serum levels for surgical management in endometrial cancer patients.MethodsA total of 995 patients with endometrial cancer, according to inclusion criteria of a preoperative serum level of CA125, were selected. The association between clinicopathological factors and CA125 were analyzed. Receiver operating characteristic (ROC) curve was used to evaluate the role of preoperative serum CA125 in predicting lymph node metastasis, adnexal involement, cervical stromal invasion in all patients, especially patients with clinical stage I. Survival analyses were also performed according to the four groups of preoperative CA125 serum levels.ResultsElevated CA125 level was significantly associated with all clinicopathological parameters, including age and menopause, but not histology type. ROC curve analysis results showed the CA125 serum level of 25 U/mL was the best cutoff to predict the lymph node metastasis. It was with 78% of sensitivity, 78% of specificity, 77.6% of false positive rate, 2.3% of false negative rate in all patients. In patients with clinical stage I, it was with 71.7% of sensitivity, 77.6% of specificity, 83.3% of false positive rate, 2.2% of false negative rate. The best cutoff to evaluate adnexal involement in patients with clinical stage I was 30U/ml, with 81% sensitivity, and 78.4% specificity. Survival analysis revealed CA125, FIGO stage, histology grade, and positive peritoneal cytology as independent prognostic factors of endometrial cancer.ConclusionPreoperative serum CA125 is an important predictor for patients with endometrial cancer and it should be taken into consideration when surgical management is determined, especially if a lymphadenectomy should be undertaken in patients with clinical stage I.

Clinical evaluation of serum CA-125 concentrations in ovary endometriosis patients

Evaluation of Sera and Peritoneal Fluid CA125 Levels in Patients with Adenomyosis of Uterus

[Value of Serum CA(125) Detection for Predicting Recurrence and Prognosis in Ovarian Epithelial Cancer].

Preoperative serum CA125: a useful marker for surgical management of endometrial cancer

The Clinical Implication of Serum CA125 Assay in Endometrial Carcinoma Patients

Diagnostic value of serum CA125, CA19-9 and CA15-3 in endometriosis: A meta-analysis

The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma

Evaluation of Serum CA125-Tn Glycoform in Peritoneal Dissemination and Surgical Completeness of High-Grade Serous Ovarian Cancer

Evaluation of Serum CA125 in Diagnosis of Epithelial Ovarian Carcinoma

Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer.

An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery

Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinoma

Combined Evaluation of Preoperative Serum CEA and CA125 As an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis

Platelet-to-Lymphocyte Ratio and CA125 Level as a Combined Biomarker for Diagnosing Endometriosis and Predicting Pelvic Adhesion Severity

Tissue and serum CA125 expression in endometrial cancer

Ovarian fibroma/fibrothecoma with elevated serum CA125 level: A cohort of 66 cases.

Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis

Diagnostic value of the combination of circulating serum miRNAs and CA125 in endometriosis

[Measurement of Serum Human Epididymis Secretory Protein 4 Combined with CA125 Assay in Differential Diagnosis of Endometriosis Cyst and Ovarian Benign and Malignant Tumors].

Evaluating pretreatment serum CA-125 levels as prognostic biomarkers in endometrial cancer: a comprehensive meta-analysis